All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The anti-CD70 TriCAR is a novel chimeric antigen receptor (CAR) constructed for the engineering of T cells to target Human CD70.More specifically, the TriCAR is a CAR-T with unique TriTE (Tri-functional T cell Engager) construct. In general, TriTE is a fusion protein with unique functions including T cell engagement, T cell stimulation, and check point blocking. It consists of five components, including R1(antigen binding domain), R2 (anti-CD3, here refer to the CD28/4-1BB-CD3ζ intracellular constimulatory domain), R3 & R4(IL15 binding domain), and R5 (PD1 for binding to PD-L1). Therefore, the TriCAR contains an anti-antigen scFv, a PD-L1 blocker, and a cytokine complex, enabling the TriCAR/SILK to simultaneously targeting the antigen-specific cancer cells, blocking the inhibitory PD-L1 signal and stimulating innate T/NK cell activation and expansion, thus make it a tri-functional CAR (Tri-CAR).
There are currently no customer reviews or questions for Anti-CD70 TriCAR (VHVL) (scFv-Sushi Domain-CD28-CD3ζ-PP2A-IL15-Anti-PD-L1), pCDCAR1 (TriCAR-Z361). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION